SAN DIEGO, Calif., May 1, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Deutsche Bank 39th Annual Healthcare Conference to be held at the InterContinental Hotel in Boston, MA, May 7-8, 2014.
Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 2:50 p.m. ET on Thursday, May 8, 2014. The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com. An audio replay will be available until June 8, 2014 following the initial presentation webcast.
About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently in a registrational Phase 3 clinical trial, referred to as QUANTUM-R, in patients with relapsed/refractory FLT3-ITD positive, acute myeloid leukemia (AML). Quizartinib is also being studied in newly diagnosed patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.
Andrew McDonald, Ph.D.
Executive Director, Investor Relations & Corp Comm
LifeSci Advisors, LLC
Ambit Biosciences Corporation
SOURCE Ambit Biosciences